That’s actually a pretty accurate statement generally speaking — it’s also common sense. Pharmaceutical collaborations/deals often involve an initial upfront payment, followed by milestone-based payments tied to specific development, regulatory, or sales goals. There’s nothing revolutionary about those terms of doing business—seems rather standard to me.
Regarding the “narrative” we’re supposedly trying to fit, we have yet to discover any specifics about the contractual agreements/collaborations cited in the recent 10-Q beyond those that were already announced. Of course, there are some reasonable possibilities that we can speculate about based on current or recently concluded clinical trials involving combos with DCVax-L (UCLA), and combos with the other dendritic cell technology that NWBO owns (Roswell).
Market Data 
Markets 
AI
